Akari Therapeutics Plc (AKTX): Price and Financial Metrics


Akari Therapeutics Plc (AKTX)

Today's Latest Price: $1.68 USD

0.02 (-1.18%)

Updated Sep 29 4:00pm

Add AKTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

AKTX Daily Price Range
AKTX 52-Week Price Range

AKTX Stock Price Chart Technical Analysis Charts


AKTX Price/Volume Stats

Current price $1.68 52-week high $2.79
Prev. close $1.70 52-week low $0.87
Day low $1.64 Volume 38,036
Day high $1.69 Avg. volume 256,046
50-day MA $1.80 Dividend yield N/A
200-day MA $1.83 Market Cap 26.64M

Akari Therapeutics Plc (AKTX) Company Bio


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company is based in London, United Kingdom.


AKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

AKTX Latest Social Stream


Loading social stream, please wait...

View Full AKTX Social Stream

Latest AKTX News From Around the Web

Below are the latest news stories about Akari Therapeutics Plc that investors may wish to consider to help them evaluate AKTX as an investment opportunity.

Akari Therapeutics reports Q2 results

Akari Therapeutics (AKTX): Q2 GAAP EPS of $0.00.Cash of approximately $12.7M.Press Release...

Seeking Alpha | September 1, 2020

Akari Therapeutics receives $30M capital commitment

Akari Therapeutics ([[AKTX]] +7.6%) gains access of $30M in the securities purchase commitment from Aspire Capital as it seeks to transition its lead drug nomacopan (coversin) into phase III trials following the success of phase II.The facility adds to its initial $20M deal with Aspire, one of its largest shareholders, that...

Seeking Alpha | July 1, 2020

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announces that it has entered into a Securities Purchase Agreement (the “Agreement”) of up to $30 million with Aspire Capital Fund, LLC (“Aspire Capital”). Under the terms of the Agreement, Aspire Capital has committed to purchase up to $30 million of Akari’s American Depositary Shares (“ADSs”) at Akari’s request from time to time during a period beginning on the effective date of a registration statement related to the transaction, and at prices based ...

Yahoo | July 1, 2020

Akari Therapeutics Announces Appointment of Chief Financial Officer

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, today announced the appointment of Torsten Hombeck, Ph.D., as Chief Financial Officer and member of the Company’s executive team. Dr. Hombeck has over two decades of biopharmaceutical industry experience in financial management and strategic planning, including several senior executive positions where he was responsible for finance, strategy, business and corporate development, and commercialization primarily in the U.S. Dr. Hombeck will be based out of Akari...

Yahoo | July 1, 2020

3 Biotech Stocks Under $5 With 100%-Plus Upside Potential

Biotech stocks give a whole new meaning to risk/reward plays. Unlike names inhabiting other areas of the market, these tickers can witness explosive movements in the blink of an eye, giving them a Street reputation for their high volatility.Companies in the biotech industry are unique in that their long-term growth prospects don’t necessarily hinge on quarterly profit results. Rather, clinical trial data or verdicts from regulatory bodies can have a more meaningful impact as product approvals indicate vital revenues are on the horizon. This means any positive development can act as a catalyst that sends shares skyrocketing. The flip-side, however, does hold true, so the risk-averse tend to shy away from these names.So, how are investors supposed to determine which biotech stocks are cap...

Yahoo | June 25, 2020

Read More 'AKTX' Stories Here

AKTX Price Returns

1-mo 0.00%
3-mo -29.11%
6-mo 44.60%
1-year -1.75%
3-year -72.64%
5-year -92.45%
YTD -4.00%
2019 11.46%
2018 -63.74%
2017 -38.49%
2016 -51.45%
2015 -69.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6372 seconds.